Genentech Warns of Risk for Psoriasis Drug

Genentech Inc. warned doctors of a potential anemia risk for users of its Raptiva psoriasis drug and updated earlier cautions about infections and a bleeding disorder.

Two people had a form of anemia stemming from premature destruction of red blood cells during studies conducted to win Raptiva’s U.S. approval in 2003, the South San Francisco-based company said in a letter to doctors posted on the Food and Drug Administration’s website.